Oramed Pharmaceuticals (ORMP) Stock Price, News & Analysis

Company Overview

Oramed Pharmaceuticals Inc. is a biopharmaceutical company focused on developing oral delivery technologies for biologic drugs, including proteins and peptides that are traditionally administered by injection. Its technology is designed to protect these therapies as they pass through the gastrointestinal tract and facilitate absorption into the bloodstream.

The company’s lead programs have included ORMD-0801, an oral insulin candidate developed for the treatment of diabetes, and oral formulations of other peptide-based therapies. Oramed has evaluated its candidates in clinical studies involving patients with diabetes and has also pursued partnerships and licensing opportunities to advance its oral drug-delivery platform.

Founded in 2006, Oramed is headquartered in Jerusalem, Israel, and has maintained corporate operations in the United States. Nadav Kidron has served as the company’s chief executive officer, while Professor Miriam Kidron, one of the company’s founders, has been associated with its scientific leadership. The company’s shares trade on the Nasdaq Capital Market under the symbol ORMP.

Key Stats

• Today's Range: $4.06 to $4.21
• 50-Day Range: $4.06 to $5.34
• 52-Week Range: $2.09 to $5.47
• Volume: 84,313 shs
• Average Volume: 150,603 shs
• Market Capitalization: $172.22 million
• P/E Ratio: 1.00
• Dividend Yield: 6.04%
• Price Target: N/A
• Consensus Rating: Hold

Oramed Pharmaceuticals Stock Analysis - MarketRank™

Oramed Pharmaceuticals scored higher than 29% of companies evaluated by MarketBeat, and ranked 767th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Hold

Consensus Rating

Oramed Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Oramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Oramed Pharmaceuticals is 1.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.89.

Price to Earnings Ratio vs. Sector

The P/E ratio of Oramed Pharmaceuticals is 1.00, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 195.83.

Price to Book Value per Share Ratio

Oramed Pharmaceuticals has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.35% of the float of Oramed Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Oramed Pharmaceuticals has a short interest ratio ("days to cover") of 7.33.

Change versus previous month

Short interest in Oramed Pharmaceuticals has recently increased by 9.61%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Oramed Pharmaceuticals is a leading dividend payer. It pays a dividend yield of 6.02%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Oramed Pharmaceuticals does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Oramed Pharmaceuticals is 6.07%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 3 people have searched for ORMP on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.6 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Oramed Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $225,500.00 in company stock.

Percentage Held by Insiders

20.77% of the stock of Oramed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

12.73% of the stock of Oramed Pharmaceuticals is held by institutions.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 10/21/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:ORMP
• CIK: 1176309
• Web: www.oramed.com
• Phone: (844) 967-2633
• Fax: 972-2566-0004
• Employees: 13
• Year Founded: 2006

Profitability

• EPS (Trailing Twelve Months): $4.12
• Trailing P/E Ratio: 1.00
• Forward P/E Ratio: 2.82
• P/E Growth: N/A
• Net Income: $64.05 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5.17%
• Return on Assets: -4.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.98
• Quick Ratio: 4.98

Sales & Book Value

• Annual Sales: $2 million
• Price / Sales: 86.11
• Cash Flow: $0.09 per share
• Price / Cash Flow: 45.74
• Book Value: $5.02 per share
• Price / Book: 0.82

Miscellaneous

• Outstanding Shares: 41,600,000
• Free Float: 32,957,000
• Market Cap: $172.22 million
• Optionable: Optionable
• Beta: 1.29